HU228426B1 - Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására - Google Patents
Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására Download PDFInfo
- Publication number
- HU228426B1 HU228426B1 HU9904361A HUP9904361A HU228426B1 HU 228426 B1 HU228426 B1 HU 228426B1 HU 9904361 A HU9904361 A HU 9904361A HU P9904361 A HUP9904361 A HU P9904361A HU 228426 B1 HU228426 B1 HU 228426B1
- Authority
- HU
- Hungary
- Prior art keywords
- pain
- hours
- gabapentin
- animals
- hyperalgesia
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims description 15
- 230000036407 pain Effects 0.000 title claims description 14
- 239000003814 drug Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 51
- 208000004454 Hyperalgesia Diseases 0.000 description 44
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 32
- 229960002870 gabapentin Drugs 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 238000001356 surgical procedure Methods 0.000 description 22
- 229960005181 morphine Drugs 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 229920001525 carrageenan Polymers 0.000 description 11
- 235000010418 carrageenan Nutrition 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 208000035154 Hyperesthesia Diseases 0.000 description 9
- 239000000679 carrageenan Substances 0.000 description 9
- 229940113118 carrageenan Drugs 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 9
- 208000004550 Postoperative Pain Diseases 0.000 description 8
- 230000003447 ipsilateral effect Effects 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 6
- 208000004296 neuralgia Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000000548 hind-foot Anatomy 0.000 description 5
- 230000003040 nociceptive effect Effects 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 150000002431 hydrogen Chemical group 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010065390 Inflammatory pain Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- -1 isohutyl Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000003070 anti-hyperalgesia Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 244000144993 groups of animals Species 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AYXYPKUFHZROOJ-UHFFFAOYSA-N 3-(azaniumylmethyl)-5-methylhexanoate Chemical compound CC(C)CC(CN)CC(O)=O AYXYPKUFHZROOJ-UHFFFAOYSA-N 0.000 description 1
- KQOVRFSYIUQKFW-UHFFFAOYSA-N 3-(azaniumylmethyl)heptanoate Chemical compound CCCCC(CN)CC(O)=O KQOVRFSYIUQKFW-UHFFFAOYSA-N 0.000 description 1
- HGINADPHJQTSKN-UHFFFAOYSA-M 3-ethoxy-3-oxopropanoate Chemical compound CCOC(=O)CC([O-])=O HGINADPHJQTSKN-UHFFFAOYSA-M 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- MMSOOZXXPAOBAN-UHFFFAOYSA-N C(C)(=O)O.C(C)[Li] Chemical compound C(C)(=O)O.C(C)[Li] MMSOOZXXPAOBAN-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000327799 Thallomys paedulcus Species 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- KIPLYOUQVMMOHB-MXWBXKMOSA-L [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O Chemical compound [Ca++].CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O.CN(C)[C@H]1[C@@H]2[C@@H](O)[C@H]3C(=C([O-])[C@]2(O)C(=O)C(C(N)=O)=C1O)C(=O)c1c(O)cccc1[C@@]3(C)O KIPLYOUQVMMOHB-MXWBXKMOSA-L 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 108010056028 auromycin Proteins 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- MNBODUCODDEXEE-UHFFFAOYSA-N ethyl 4,4-dimethylpent-2-enoate Chemical compound CCOC(=O)C=CC(C)(C)C MNBODUCODDEXEE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000000917 hyperalgesic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940063650 terramycin Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUS1300046C HUS1300046I1 (hu) | 1996-07-24 | 2013-08-27 | Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2233796P | 1996-07-24 | 1996-07-24 | |
| PCT/US1997/012390 WO1998003167A1 (en) | 1996-07-24 | 1997-07-16 | Isobutylgaba and its derivatives for the treatment of pain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP9904361A2 HUP9904361A2 (hu) | 2000-05-28 |
| HUP9904361A3 HUP9904361A3 (en) | 2000-11-28 |
| HU228426B1 true HU228426B1 (hu) | 2013-03-28 |
Family
ID=21809080
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904361A HU228426B1 (hu) | 1996-07-24 | 1997-07-16 | Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására |
| HUS1300046C HUS1300046I1 (hu) | 1996-07-24 | 2013-08-27 | Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUS1300046C HUS1300046I1 (hu) | 1996-07-24 | 2013-08-27 | Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | USRE41920E1 (Direct) |
| EP (1) | EP0934061B3 (Direct) |
| JP (1) | JP3693258B2 (Direct) |
| KR (1) | KR100491282B1 (Direct) |
| CN (1) | CN1094757C (Direct) |
| AT (1) | ATE241351T1 (Direct) |
| AU (1) | AU714980B2 (Direct) |
| BR (1) | BR9710536A (Direct) |
| CU (1) | CU22850A3 (Direct) |
| DE (1) | DE69722426T3 (Direct) |
| DK (1) | DK0934061T6 (Direct) |
| ES (1) | ES2200184T7 (Direct) |
| HR (1) | HRP970387A2 (Direct) |
| HU (2) | HU228426B1 (Direct) |
| IL (1) | IL126999A (Direct) |
| NO (2) | NO325822B1 (Direct) |
| NZ (1) | NZ332762A (Direct) |
| PL (1) | PL189872B1 (Direct) |
| PT (1) | PT934061E (Direct) |
| SI (1) | SI0934061T1 (Direct) |
| WO (1) | WO1998003167A1 (Direct) |
| ZA (1) | ZA976562B (Direct) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| HRP980342A2 (en) * | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| BR9812162A (pt) * | 1997-09-08 | 2000-07-18 | Warner Lambert Co | Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas |
| EP0974351A3 (en) * | 1998-04-24 | 2000-12-13 | Jouveinal | Medicament for preventing and treating gastrointestinal damage |
| EP1077692B1 (en) * | 1998-05-15 | 2004-07-28 | Warner-Lambert Company LLC | Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| ATE305778T1 (de) * | 1998-07-09 | 2005-10-15 | Warner Lambert Co | Behandlung von nierenkolik mit gaba-analogen |
| US20030045500A1 (en) * | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| EP1093365A2 (en) * | 1998-07-09 | 2001-04-25 | Warner-Lambert Company | Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain |
| AU765246B2 (en) * | 1998-07-09 | 2003-09-11 | Warner-Lambert Company | Pharmaceutical composition containing gaba analogs and an antiviral agent to treat shingles |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| AU3735000A (en) * | 1999-05-05 | 2000-11-21 | Warner-Lambert Company | Modulation of substance p by gaba analogs and methods relating thereto |
| EA004398B1 (ru) * | 1999-06-10 | 2004-04-29 | Уорнер-Ламберт Компани | Одно- и двузамещенные 3-пропил-гамма-аминомасляные кислоты |
| US20080207755A1 (en) * | 2000-05-31 | 2008-08-28 | Pfizer Inc | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders |
| EP1840117A1 (en) * | 1999-06-10 | 2007-10-03 | Warner-Lambert Company LLC | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
| US7164034B2 (en) * | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
| HU228815B1 (en) * | 2000-01-27 | 2013-05-28 | Warner Lambert Co | Asymmetric synthesis of pregabalin |
| US6687187B2 (en) * | 2000-08-11 | 2004-02-03 | Phonak Ag | Method for directional location and locating system |
| CA2356829A1 (en) * | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) * | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| EP1243262B1 (en) * | 2001-03-20 | 2006-05-31 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain |
| EP1243263B1 (en) * | 2001-03-21 | 2002-11-27 | Schwarz Pharma Ag | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain |
| US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| ATE540678T1 (de) * | 2001-06-11 | 2012-01-15 | Xenoport Inc | Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen |
| US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| WO2002100344A2 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| US6927036B2 (en) * | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| WO2003099338A2 (en) * | 2002-05-17 | 2003-12-04 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
| US7273889B2 (en) * | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| AU2003297927A1 (en) * | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof |
| WO2004053192A1 (en) * | 2002-12-11 | 2004-06-24 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| EP1572187A1 (en) * | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| MXPA05005815A (es) * | 2002-12-13 | 2005-08-18 | Warner Lambert Co | Analogos de gabapentina para fibromialgia y otros trastornos. |
| PT1572173E (pt) | 2002-12-13 | 2010-05-10 | Warner Lambert Co | Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior |
| NZ540591A (en) * | 2002-12-13 | 2008-03-28 | Warner Lambert Co | Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| US20080318908A1 (en) * | 2002-12-17 | 2008-12-25 | Trustees Of Tufts College | Use of gaba and gabab agonists |
| CA2537402C (en) * | 2003-09-12 | 2009-05-05 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| CN1871021B (zh) * | 2003-09-17 | 2010-07-28 | 什诺波特有限公司 | 用gaba类似物的前药治疗或预防多动腿综合征 |
| NZ546381A (en) | 2003-10-14 | 2010-01-29 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog |
| EP1689378B1 (en) * | 2003-12-02 | 2009-04-15 | Schwarz Pharma Ag | Novel use of peptide compounds for treating central neuropathic pain |
| AU2005221401A1 (en) * | 2004-03-12 | 2005-09-22 | Warner-Lambert Company Llc | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin |
| US20070042969A1 (en) * | 2004-03-26 | 2007-02-22 | Srz Properties, Inc. | Combination therapy for pain in painful diabetic neuropathy |
| US20100256179A1 (en) * | 2004-03-26 | 2010-10-07 | Ucb Pharma Gmbh | Combination therapy for pain in painful diabetic neuropathy |
| BRPI0508998A (pt) * | 2004-04-01 | 2007-09-04 | Warner Lambert Co | preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica |
| EA013591B1 (ru) | 2004-04-16 | 2010-06-30 | Шварц Фарма Аг | Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd) |
| EP1604655A1 (en) * | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating pain in trigeminal neuralgia |
| PT1831154E (pt) * | 2004-06-21 | 2010-02-19 | Warner Lambert Co | Preparação de pregabalina e compostos relacionados |
| PL1781276T3 (pl) * | 2004-08-27 | 2010-11-30 | Ucb Pharma Gmbh | Zastosowanie związków peptydowych do leczenia bólu związanego z rakiem kości, bólu indukowanego przez chemioterapię oraz nukleozydy |
| RU2440112C2 (ru) | 2004-11-04 | 2012-01-20 | Ксенопорт, Инк. | Пероральная дозированная форма габапентина замедленного высвобождения |
| US7763749B2 (en) * | 2005-05-10 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Method for the preparation of Pregabalin and salts thereof |
| US20070043241A1 (en) | 2005-05-10 | 2007-02-22 | Lilach Hedvati | Optical resolution of 3-carbamoylmethyl-5-methylhexanoic acid |
| US20080293698A1 (en) * | 2005-05-16 | 2008-11-27 | Joseph Johnson | Methods and Compositions for Treating Arg |
| US20080269310A1 (en) * | 2005-05-20 | 2008-10-30 | Adrian Paul Foster | Synergistic Combinations |
| EP1754476A1 (en) * | 2005-08-18 | 2007-02-21 | Schwarz Pharma Ag | Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| US20070048372A1 (en) * | 2005-08-18 | 2007-03-01 | Srz Properties, Inc. | Method for treating non-inflammatory osteoarthritic pain |
| WO2007035789A1 (en) * | 2005-09-19 | 2007-03-29 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the new synthesis of (s)-pregabalin |
| WO2007139933A2 (en) * | 2006-05-24 | 2007-12-06 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of r-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof |
| AU2007260207B2 (en) * | 2006-06-15 | 2012-11-08 | Ucb Pharma Gmbh | Pharmaceutical composition with synergistic anticonvulsant effect |
| BRPI0803092A2 (pt) * | 2007-03-22 | 2011-08-30 | Teva Pharma | sìntese de (s)-(+)-3-(aminometil)-5-metil ácido hexanóico, (s)-pregabalina |
| KR20090101462A (ko) * | 2007-10-03 | 2009-09-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | 프레가발린-4-엘리미네이트, 프레가발린 5-엘리미네이트, 기준 마커 및 표준물로서의 이들의 용도, 및 이들을 낮은 수준으로 함유하는 프레가발린의 제조 방법 |
| WO2009158343A1 (en) * | 2008-06-23 | 2009-12-30 | Teva Pharmaceutical Industries, Ltd. | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
| WO2010070593A2 (en) | 2008-12-19 | 2010-06-24 | Pfizer Ireland Pharmaceuticals | Malonate esters |
| US9192681B2 (en) | 2009-02-24 | 2015-11-24 | Nektar Therapeutics | Oligomer-amino acid conjugates |
| NZ610978A (en) | 2009-05-15 | 2014-11-28 | Redx Pharma Ltd | Redox drug derivatives |
| WO2010150221A1 (en) | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Taste masked pharmaceutical compositions of pregabalin |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| CA2783699C (en) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Primary amine compounds for treating ocular disorders |
| HU230031B1 (hu) | 2010-03-01 | 2015-05-28 | Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság | Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény |
| WO2011141923A2 (en) | 2010-05-14 | 2011-11-17 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
| EP2575798B1 (en) | 2010-06-01 | 2017-08-09 | Rubicon Research Private Limited | Gastroretentive dosage forms of gaba analogs |
| WO2012025861A1 (en) | 2010-08-23 | 2012-03-01 | Pfizer Manufacturing Ireland | Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin |
| US8466297B2 (en) | 2010-11-01 | 2013-06-18 | Milan Soukup | Manufacturing process for (S)-Pregabalin |
| WO2012059797A1 (en) | 2010-11-04 | 2012-05-10 | Lupin Limited | Process for synthesis of (s) - pregabalin |
| EP2809304A1 (en) | 2012-01-30 | 2014-12-10 | Ranbaxy Laboratories Limited | Gastroretentive tablets |
| CA2863371A1 (en) | 2012-01-30 | 2013-08-08 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
| CN102966602B (zh) * | 2012-12-14 | 2015-08-05 | 江苏海鸥冷却塔股份有限公司 | 一种冷却塔节能导流风筒 |
| WO2014112152A1 (ja) | 2013-01-18 | 2014-07-24 | 有限会社ケムフィズ | 神経因性疾病の治療のための医薬 |
| CN105051022B (zh) | 2013-03-27 | 2017-10-27 | 辉瑞爱尔兰制药公司 | 用于制备普瑞巴林的方法和中间体 |
| CN107920987A (zh) | 2015-05-26 | 2018-04-17 | 艾萨·欧蒂迪 | 控制延缓释放普瑞巴林 |
| GB201617380D0 (en) | 2016-10-13 | 2016-11-30 | St George's Hospital Medical School | Treatment for Osteoarthritis |
| KR102039344B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 경구용 서방성 삼중정제 |
| KR102039345B1 (ko) | 2017-02-01 | 2019-11-01 | 지엘팜텍주식회사 | 프레가발린 함유 고팽윤성 서방성 삼중정제 |
| GB201703123D0 (en) * | 2017-02-27 | 2017-04-12 | St George's Hospital Medical School | Biomarkers |
| CA3099775A1 (en) | 2018-05-14 | 2019-11-21 | Xgene Pharmaceutical Inc. | Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin |
| CN108926573A (zh) * | 2018-07-03 | 2018-12-04 | 泓博元生命科技（深圳）有限公司 | 一种可降低尿酸指数的nadh组合物及其制备方法及应用 |
| KR20200056719A (ko) | 2018-11-15 | 2020-05-25 | 단국대학교 천안캠퍼스 산학협력단 | 가바펜티노이드를 포함하는, 척수손상 개체의 신경재생 또는 신경회복을 위한 조성물 |
| MX2022009050A (es) | 2020-01-22 | 2022-10-27 | Seelos Therapeutics Inc | Reduccion de los efectos secundarios de los antagonistas de nmda. |
| WO2021191108A1 (en) | 2020-03-23 | 2021-09-30 | Plus Vitech, S.L. | Treatment or prevention of acute organ damage induced by viral infection with a nk1 inhibitor and/or a gabapentinoid |
| WO2022038131A1 (en) | 2020-08-19 | 2022-02-24 | Plus Vitech, S.L. | Method for the prediction of progression or prognosis of the response of a subject suffering from acute organ damage |
| HU231397B1 (hu) | 2021-01-22 | 2023-06-28 | Egis Gyógyszergyár Zrt. | Pregabalint tartalmazó topikális gyógyszerkészítmény |
| AU2022210509A1 (en) | 2021-01-22 | 2023-08-17 | Egis Gyógyszergyár Zrt. | Topical formulation containing dispersed pregabalin |
| WO2022234110A1 (en) | 2021-05-07 | 2022-11-10 | Plus Vitech, S.L. | Gamma-aminobutyric acid derivatives for use in cancer therapy |
| WO2022243430A1 (en) | 2021-05-20 | 2022-11-24 | Plus Vitech, S.L. | Treatment of acne |
| WO2022253748A1 (en) | 2021-06-03 | 2022-12-08 | Plus Vitech, S.L. | Combinations for the treatment of hpv |
Family Cites Families (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| JPS4940460Y2 (Direct) | 1971-05-19 | 1974-11-06 | ||
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| US4123438A (en) | 1975-03-05 | 1978-10-31 | Stamicarbon, B.V. | Process for preparing 2-pyrrolidones |
| NZ194348A (en) | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| US4322440A (en) | 1980-06-25 | 1982-03-30 | New York University | Anticonvulsive compositions and method of treating convulsive disorders |
| US4513135A (en) | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| DK373383A (da) | 1982-08-20 | 1984-02-21 | Midit | Fremgangsmaade til fremstilling af omega-aminosyrederivater |
| US4479005A (en) | 1982-12-16 | 1984-10-23 | The Dow Chemical Company | Selective preparation of isomers and enantiomers of cyclopropane carboxylic acids |
| EP0133795B1 (en) | 1983-08-01 | 1989-01-18 | THE McLEAN HOSPITAL CORPORATION | Gaba esters and gaba analogue esters |
| US5051448A (en) | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
| GB8425872D0 (en) | 1984-10-12 | 1984-11-21 | Ciba Geigy Ag | Chemical compounds |
| DK170473B1 (da) | 1985-06-20 | 1995-09-11 | Daiichi Seiyaku Co | S(-)-pyridobenzoxazinforbindelser |
| US4956388A (en) | 1986-12-22 | 1990-09-11 | Eli Lilly And Company | 3-aryloxy-3-substituted propanamines |
| JP2535001B2 (ja) | 1987-01-13 | 1996-09-18 | ダイセル化学工業株式会社 | Ｎ−アルキル化アミノ酸エステルの製法 |
| JPH07116064B2 (ja) | 1987-07-21 | 1995-12-13 | 三菱化学株式会社 | 分離剤 |
| US4908210A (en) | 1988-10-28 | 1990-03-13 | Eastman Kodak Company | Lactylic salt tablet formulations and tablets |
| GB8911017D0 (en) | 1989-05-13 | 1989-06-28 | Ciba Geigy Ag | Substituted aminoalkylphosphinic acids |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| GB8921304D0 (en) | 1989-09-20 | 1989-11-08 | Wyeth John & Brother Ltd | New method of treatment and heterocyclic compounds used therein |
| US5104869A (en) | 1989-10-11 | 1992-04-14 | American Cyanamid Company | Renin inhibitors |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US5025035A (en) | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| WO1992014443A1 (en) | 1991-02-20 | 1992-09-03 | Warner-Lambert Company | Microsphere-in-oil emulsion |
| DK204791D0 (da) | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
| HU222776B1 (hu) | 1992-05-20 | 2003-10-28 | Northwestern University | (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása |
| GB9308430D0 (en) | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
| US5492927A (en) | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
| US5792796A (en) | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| PL187064B1 (pl) | 1994-07-27 | 2004-05-31 | Warner Lambert Co | Zastosowania gabapentyny do leczenia i/lub zapobiegania stanom lękowym |
| GB9420784D0 (en) | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
| US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
| ATE279406T1 (de) | 1995-01-12 | 2004-10-15 | Glaxo Group Ltd | Piperidinderivate mit tachykinin-antagonistischer wirkung |
| IL117295A (en) | 1995-02-28 | 1999-11-30 | Lundbeck & Co As H | 4-Aminotetrahydro-benzisoxazole or-isothiazole compounds and pharmaceutical compositions comprising them |
| US5510381A (en) | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
| US5616793A (en) | 1995-06-02 | 1997-04-01 | Warner-Lambert Company | Methods of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US5637767A (en) | 1995-06-07 | 1997-06-10 | Warner-Lambert Company | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
| US5929088A (en) | 1996-02-07 | 1999-07-27 | Warner-Lambert Company | Cyclic amino acids as pharmaceutical agents |
| EE9800309A (et) | 1996-03-14 | 1999-02-15 | Warner-Lambert Company | Uued asendatud tsüklilised aminohapped kui farmatseutilised toimeained |
| JP2000506862A (ja) | 1996-03-14 | 2000-06-06 | ワーナー―ランバート・コンパニー | 医薬としての新規な架橋環状アミノ酸 |
| US20020077461A1 (en) | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
| US6372792B1 (en) | 1996-04-26 | 2002-04-16 | Guy Chouinard | Method for treating anxiety, anxiety disorders and insomnia |
| CA2255651A1 (en) | 1996-06-26 | 1997-12-31 | Warner-Lambert Company | Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis |
| SE9603408D0 (sv) | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| HRP980342A2 (en) | 1997-06-25 | 1999-02-28 | Warner Lambert Co | Anti-inflammatory method |
| US6329429B1 (en) | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
| WO1999008667A2 (en) | 1997-08-19 | 1999-02-25 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
| US6127418A (en) | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
| WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
| BR9812162A (pt) | 1997-09-08 | 2000-07-18 | Warner Lambert Co | Composições analgésicas compreendendo compostos antiepiléticos e métodos para o uso das mesmas |
| HUP0100472A3 (en) | 1997-12-16 | 2003-03-28 | Warner Lambert Co | Novel amines as pharmaceutical agents |
| HU228772B1 (en) | 1998-05-15 | 2013-05-28 | Warner Lambert Co | Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same |
| EP1077692B1 (en) | 1998-05-15 | 2004-07-28 | Warner-Lambert Company LLC | Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same |
| US20030045500A1 (en) | 1998-07-09 | 2003-03-06 | Leslie Magnus | Pharmaceutical composition containing GABA analogs and an antiviral agent to treat shingles |
| JP2002520277A (ja) | 1998-07-09 | 2002-07-09 | ワーナー−ランバート・カンパニー | 不眠症を治療する方法 |
| US6680343B1 (en) | 1998-07-09 | 2004-01-20 | Warner-Lambert Comapny | Treatment of renal colic with GABA analogs |
| CA2332915C (en) | 1998-07-09 | 2006-10-24 | Warner-Lambert Company | Compositions comprising gaba analogs and caffeine |
| CA2344407C (en) | 1998-10-16 | 2007-01-09 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| EP1161263A1 (en) | 1999-03-10 | 2001-12-12 | Warner-Lambert Company Llc | Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| KR20010108466A (ko) | 1999-04-09 | 2001-12-07 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 우울증 치료용 ｇａｂａ 유사체와 삼환계 화합물의 복합제제 |
| JP2003525207A (ja) | 1999-06-02 | 2003-08-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 薬剤として有用なアミノ複素環 |
| US7164034B2 (en) | 1999-06-10 | 2007-01-16 | Pfizer Inc. | Alpha2delta ligands for fibromyalgia and other disorders |
| US6642398B2 (en) | 1999-06-10 | 2003-11-04 | Warner-Lambert Company | Mono-and disubstituted 3-propyl gamma-aminobutyric acids |
| EP1196160B1 (en) | 1999-07-02 | 2005-12-21 | Warner-Lambert Company Llc | A synergistic combination: gabapentin and pregabalin |
| US7030119B1 (en) | 1999-07-16 | 2006-04-18 | Warner-Lambert Company | Method for treating chronic pain using MEK inhibitors |
| JP2003512602A (ja) | 1999-09-16 | 2003-04-02 | ワーナー−ランバート・カンパニー | α２δ−１サブユニット結合リガンドのスクリーニング方法 |
| AP2002002501A0 (en) | 1999-10-07 | 2002-06-30 | Warner Lambert Co | Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog. |
| HU228815B1 (en) | 2000-01-27 | 2013-05-28 | Warner Lambert Co | Asymmetric synthesis of pregabalin |
| US20010036943A1 (en) | 2000-04-07 | 2001-11-01 | Coe Jotham W. | Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| AU2001259627A1 (en) | 2000-05-16 | 2001-11-26 | Warner Lambert Company | Cell line for the expression of an alpha2delta2 calcium channel subunit |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| CA2356829A1 (en) | 2000-09-22 | 2002-03-22 | Warner-Lambert Company | Method for treating asthma using pregabalin |
| US6620829B2 (en) | 2000-10-17 | 2003-09-16 | Warner-Lambert Company | Method of treating noninflammatory cartilage damage |
| BR0115783A (pt) | 2000-11-30 | 2003-09-16 | Pfizer Prod Inc | Combinação de agonistas de gaba e inibidores de sorbitol desidrogenase |
| AU2002215160A1 (en) | 2000-11-30 | 2002-06-11 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
| MXPA03004168A (es) | 2000-12-13 | 2004-12-02 | Warner Lambert Co | Sintesis de ligandos bisfosfolanos p-quirales y de sus complejos con metales de transicion para uso como catalizadores de hidrogenacion asimetrica. |
| US20040002543A1 (en) | 2001-02-16 | 2004-01-01 | Leslie Magnus | Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain |
| DE60204611T2 (de) | 2001-02-28 | 2006-05-11 | Pfizer Products Inc., Groton | Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren |
| MXPA02001147A (es) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Sintesis de ligandos bisfosina no-c2-simetricos como catalizadores para la hidrogenacion asimetrica. |
| US7022678B2 (en) | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| PL365294A1 (en) | 2001-03-30 | 2004-12-27 | Pfizer Products Inc. | Pyridazinone aldose reductase inhibitors |
| EP1247809A3 (en) | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| WO2002085839A1 (en) | 2001-04-19 | 2002-10-31 | Warner-Lambert Company Llc | Fused bicyclic or tricyclic amino acids |
| JP2004534764A (ja) | 2001-05-25 | 2004-11-18 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 液状医薬組成物 |
| US20030045449A1 (en) | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| DE10203122A1 (de) | 2002-01-25 | 2003-07-31 | Gruenenthal Gmbh | Verfahren zur Herstellung von substituierten Acrylsäureestern bzw. deren Einsatz zur Herstellung von substituierten gamma-Aminosäuren |
| NZ532624A (en) | 2002-01-31 | 2007-05-31 | Warner Lambert Co | Alpha2delta ligands to treat tinnitus |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| US6713490B2 (en) | 2002-04-26 | 2004-03-30 | Pfizer, Inc. | 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists |
| US20030225149A1 (en) | 2002-04-30 | 2003-12-04 | Blazecka Peter G. | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids |
| EP1515709A2 (en) | 2002-06-27 | 2005-03-23 | Warner-Lambert Company LLC | Use of an alpha2delta ligand such as gabapentin or pregabalin for treating attention deficit hyperactivity disorder |
| BR0312575A (pt) | 2002-07-08 | 2005-05-03 | Pfizer Prod Inc | Moduladores do receptor de glicocorticóides |
| US7053122B2 (en) | 2002-08-09 | 2006-05-30 | Pfizer Inc | Therapeutic use of aryl amino acid derivatives |
| US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US20040092522A1 (en) | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7071339B2 (en) | 2002-08-29 | 2006-07-04 | Warner Lambert Company Llc | Process for preparing functionalized γ-butyrolactones from mucohalic acid |
| US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
| BR0316386A (pt) | 2002-12-06 | 2005-09-27 | Warner Lambert Co | Benzoxazin-3-onas e seus derivados como inibidores de p13k |
| EP1572187A1 (en) | 2002-12-13 | 2005-09-14 | Warner-Lambert Company LLC | Pregabalin and derivatives thereof for the treatment of fibromyalgia and other related disorders |
| CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| US7572910B2 (en) | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| WO2004100992A2 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
| CA2527779A1 (en) | 2003-06-05 | 2004-12-16 | Warner-Lambert Company Llc | 3-substituted indoles and derivatives thereof as therapeutic agents |
| WO2005002585A1 (en) | 2003-07-02 | 2005-01-13 | Warner-Lambert Company Llc | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| DK1664036T3 (da) | 2003-09-03 | 2012-02-13 | Pfizer | Benzimidazolonforbindelser med 5-HT4-receptoragonistisk virkning |
| CA2537402C (en) | 2003-09-12 | 2009-05-05 | Pfizer Inc. | Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors |
| JP2007505095A (ja) | 2003-09-12 | 2007-03-08 | ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー | うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ |
| GB0322140D0 (en) | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
| EP1670750A1 (en) | 2003-09-25 | 2006-06-21 | Warner-Lambert Company LLC | Prodrugs of amino acids with affinity for the alpha2delta- protein |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| EP1543831A1 (en) | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
| EP1737466A1 (en) | 2004-01-29 | 2007-01-03 | Pfizer Products Inc. | COMBINATION OF y-AMINOBUTYRIC ACID MODULATORS AND 5-HT-1b RECEPTOR ANTAGONISTS |
| GB0405200D0 (en) | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
| AU2005221401A1 (en) | 2004-03-12 | 2005-09-22 | Warner-Lambert Company Llc | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin |
| BRPI0509307A (pt) | 2004-03-29 | 2007-09-04 | Pfizer | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 |
| BRPI0508998A (pt) | 2004-04-01 | 2007-09-04 | Warner Lambert Co | preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica |
| CA2562251C (en) | 2004-04-07 | 2009-04-28 | Pfizer Inc. | Pyrazolo'4,3-d pyrimidines |
| UA82292C2 (uk) | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | Спосіб стереоселективного біоперетворення аліфатичних динітрилів в ціанокарбонові кислоти (варіанти) |
| MXPA06011891A (es) | 2004-04-20 | 2007-04-24 | Pfizer | Metodo para tratar el dolor neuropatico. |
| MXPA06012172A (es) | 2004-04-20 | 2007-01-17 | Pfizer Prod Inc | Combinaciones que comprenden ligandos alfa-2-delta y antagonistas del receptor ep4. |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| AP2006003771A0 (en) | 2004-04-30 | 2006-10-31 | Warner Lambert Co | Substituted morpholine compounds for the treatmentof central nervous system disorders |
| US7737163B2 (en) | 2004-06-15 | 2010-06-15 | Pfizer Inc. | Benzimidazolone carboxylic acid derivatives |
| EP1758891A2 (en) | 2004-06-15 | 2007-03-07 | Pfizer Japan Inc. | Benzimidazolone carboxylic acid derivatives |
| PT1831154E (pt) | 2004-06-21 | 2010-02-19 | Warner Lambert Co | Preparação de pregabalina e compostos relacionados |
| MXPA06014022A (es) | 2004-06-29 | 2007-02-08 | Pfizer Prod Inc | Prcedimientos para preparar inhibidores de p2x7. |
| US20060003344A1 (en) | 2004-06-30 | 2006-01-05 | Pfizer Inc. | Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40 |
| WO2006008640A1 (en) | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| US7649004B2 (en) | 2004-07-23 | 2010-01-19 | Pfizer, Inc. | Pyridine derivatives |
| GB0419849D0 (en) | 2004-09-07 | 2004-10-13 | Pfizer Ltd | Pharmaceutical combination |
| MX2007005290A (es) | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
| AP2007004024A0 (en) | 2004-11-29 | 2007-06-30 | Warner Lambert Co | Therapeutic pyrazoloÄ3,4-BÜpyridines and indazoles |
| AP2007004067A0 (en) | 2005-02-22 | 2007-08-31 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| WO2006092692A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
| ATE443056T1 (de) | 2005-03-10 | 2009-10-15 | Pfizer | Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen |
| BRPI0608436A2 (pt) | 2005-03-17 | 2009-12-29 | Pfizer | derivados de n-(n-sulfonilaminometil) ciclopropanocarboxamida utilizáveis para o tratamento de dor |
| JP2008536910A (ja) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体 |
| EP1879567A1 (en) | 2005-04-28 | 2008-01-23 | Pfizer Limited | Amino acid derivatives |
| US20080269310A1 (en) | 2005-05-20 | 2008-10-30 | Adrian Paul Foster | Synergistic Combinations |
| CA2610354C (en) | 2005-05-31 | 2011-03-29 | Pfizer Inc. | Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists |
| NL2000281C2 (nl) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Vaste farmaceutische samenstellingen die pregabaline bevatten. |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| ATE537150T1 (de) | 2005-11-08 | 2011-12-15 | Pfizer Ltd | Zur behandlung gynäkologischer erkrankungen geeignete pyrazolderivate |
| BRPI0619126A2 (pt) | 2005-12-02 | 2011-09-13 | Pfizer Ltd | derivados espirocìclicos, composição farmacêutica e usos dos mesmos |
| CA2530904C (en) | 2005-12-20 | 2013-10-08 | John Marino | Pharmaceutical agents for the treatment of pain associated with spinal cord injury |
| CN101420947A (zh) | 2006-03-06 | 2009-04-29 | 辉瑞产品公司 | 用于非恢复性睡眠的α-2-δ配体 |
| GB0700786D0 (en) | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
| DK2114970T3 (da) | 2007-02-02 | 2011-09-19 | Pfizer Prod Inc | Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer |
| WO2008132589A1 (en) | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
-
1997
- 1997-07-16 CN CN97196041A patent/CN1094757C/zh not_active Expired - Lifetime
- 1997-07-16 WO PCT/US1997/012390 patent/WO1998003167A1/en not_active Ceased
- 1997-07-16 BR BR9710536A patent/BR9710536A/pt not_active Application Discontinuation
- 1997-07-16 AU AU36024/97A patent/AU714980B2/en not_active Expired
- 1997-07-16 HU HU9904361A patent/HU228426B1/hu active Protection Beyond IP Right Term
- 1997-07-16 AT AT97932617T patent/ATE241351T1/de active
- 1997-07-16 KR KR10-1999-7000577A patent/KR100491282B1/ko not_active Expired - Lifetime
- 1997-07-16 US US11/983,750 patent/USRE41920E1/en not_active Expired - Lifetime
- 1997-07-16 DK DK97932617.0T patent/DK0934061T6/en active
- 1997-07-16 DE DE1997622426 patent/DE69722426T3/de not_active Expired - Lifetime
- 1997-07-16 SI SI9730545T patent/SI0934061T1/xx unknown
- 1997-07-16 PT PT97932617T patent/PT934061E/pt unknown
- 1997-07-16 PL PL97331325A patent/PL189872B1/pl unknown
- 1997-07-16 US US09/043,358 patent/US6001876A/en not_active Expired - Lifetime
- 1997-07-16 JP JP50706298A patent/JP3693258B2/ja not_active Expired - Lifetime
- 1997-07-16 IL IL12699997A patent/IL126999A/en not_active IP Right Cessation
- 1997-07-16 EP EP97932617.0A patent/EP0934061B3/en not_active Expired - Lifetime
- 1997-07-16 NZ NZ332762A patent/NZ332762A/xx not_active IP Right Cessation
- 1997-07-16 ES ES97932617.0T patent/ES2200184T7/es active Active
- 1997-07-17 HR HR60/022,337A patent/HRP970387A2/hr not_active Application Discontinuation
- 1997-07-23 ZA ZA9706562A patent/ZA976562B/xx unknown
-
1999
- 1999-01-22 CU CU1999008A patent/CU22850A3/es unknown
- 1999-01-22 NO NO19990279A patent/NO325822B1/no not_active IP Right Cessation
-
2008
- 2008-12-04 NO NO2008018C patent/NO2008018I2/no unknown
-
2013
- 2013-08-27 HU HUS1300046C patent/HUS1300046I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU228426B1 (hu) | Izobutil-gaba és származékai alkalmazása fájdalom kezelésére alkalmas gyógyszer elõállítására | |
| ES2284523T3 (es) | Sales farmaceuticas de tramadol. | |
| EP2892518B1 (en) | Compositions for treating parkinson's disease | |
| EP2201943B1 (en) | Novel use of a peptide class of compounds for treating diabetic neuropathic pain | |
| TW200936123A (en) | Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain | |
| AU2002257680A1 (en) | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | |
| CN102573825B (zh) | 曲马多与昔布类的共晶体 | |
| JP2003055214A (ja) | ２−フェニル−１−（３，４−ジヒドロキシ−５−ニトロフェニル）−１−エタノン置換化合物、中枢および末梢神経系障害治療における同化合物の使用法、および、同化合物を含有する薬剤組成物。 | |
| CA2255652E (en) | Isobutylgaba and its derivatives for the treatment of pain | |
| AU2014308958A1 (en) | Pharmaceutical composition and use of diethyl (2-cyanoethyl)phosphonate | |
| HK1021134B (en) | Isobutylgaba and its derivatives for the treatment of pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: PREGABALIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REG. NO/DATE: EU/1/04/279/001-EU/1/04/279/025 20040706 Spc suppl protection certif: S1300046 Filing date: 20130827 Expiry date: 20170716 |
|
| GB9A | Succession in title |
Owner name: WARNER-LAMBERT COMPANY LLC, US Free format text: FORMER OWNER(S): WARNER-LAMBERT CO., US |
|
| FH91 | Appointment of a representative |
Free format text: FORMER REPRESENTATIVE(S): S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU Representative=s name: SAR ES TARSAI UEGYVEDI IRODA, HU |
|
| FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: PREGABALIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTRATION NO/DATE: EU/1/04/279/001-EU/1/04/279/025 20040708 Spc suppl protection certif: S1300046 Filing date: 20130827 Expiry date: 20170716 Extension date: 20190709 |